Table 1 Baseline characteristics of enrolled RA patients.
RA patients (N = 109) | |
|---|---|
Age (years) | 52.0 [46.0; 63.0] |
Female (n, %) | 97 (89.0%) |
Disease duration (years) | 2.0 [1.0; 6.1] |
BMI (kg/m2) | 22.4 [20.5; 24.7] |
Regular exercise (yes) | 47 (43.1%) |
Smoking | |
Nonsmoker | 97 (89.0%) |
Ex-smoker | 6 (5.5%) |
Current smoker | 6 (5.5%) |
Baseline Td joint (yes) | 17 (15.6%) |
Baseline swollen joint (yes) | 22 (20.2%) |
Baseline erosions of hands or feet | 30 (27.5%) |
Baseline JSN of hands or feet | 39 (35.8%) |
Medication | |
Methotrexate | 92 (84.4%) |
Hydroxychloroquine | 5 (4.6%) |
Sulfasalazine | 1 (0.9%) |
Leflunomide | 2 (1.8%) |
NSAIDs | 92 (86.8%) |
Glucocorticoid dose (mg/day, equivalent to prednisolone) | 2.5 [2.0; 5.0] |
Previous bDMARDs use history (yes) | 13 (11.9%) |
Adalimumab | 6 |
Etanercept | 4 |
Infliximab | 3 |
Current TNFi | |
Adalimumab | 48 (44.0%) |
Etanercept | 61 (56.0%) |
Laboratory findings | |
CRP (mg/dL) | 0.4 [0.3; 1.1] |
ESR (mm/hr) | 26.0 [13.0; 45.0] |
RF positive | 90 (82.6%) |
ACPA positive | 79 (72.5%) |
PhGA (0–100) | 22.0 [11.0; 36.0] |
PtGA (0–100) | 32.0 [13.0; 57.0] |
Baseline DAS28 | 4.0 [3.2; 5.0] |
Baseline HAQ | 0.8 [0.4; 1.2] |
